Brian Hubbard

Private Equity Investor at

Sprout Bioventures

Health Technology

Consumer Services

Finance

Profile

Brian Hubbard currently works at Sprout Bioventures, as Partner from 2018.
Dr. Hubbard also formerly worked at Dogma Therapeutics, Inc., as Chief Executive officer from 2015 to 2020, Novartis AG, as Director from 2002 to 2008, The Broad Institute, Inc., as Director from 2011 to 2015, and Merck Global Health Innovation LLC, as Sr. Director from 2008 to 2011.
Dr. Hubbard received his undergraduate degree in 1994 from The College of William & Mary, doctorate degree from the University of Illinois, and graduate degree from Harvard Medical School.

Brian Hubbard active positions

Companies	Position	Start
Sprout Bioventures Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions.	Private Equity Investor	01/01/2018

All active positions of Brian Hubbard

Former positions of Brian Hubbard

Companies	Position	End
Dogma Therapeutics, Inc. Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease	Chief Executive Officer	02/08/2020
The Broad Institute, Inc. The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases	Director of Research - Equity	02/08/2015
Merck Global Health Innovation LLC Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million.	Director of Research - Equity	02/09/2011
NOVARTIS AG	Director of Research - Equity	02/01/2008

See the detail of Brian Hubbard's experience

Training of Brian Hubbard

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Brian Hubbard's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
Novartis AG Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products	Health Technology
The College of William & Mary The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Illinois University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Broad Institute, Inc. The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases	Health Technology
Harvard Medical School Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Merck Global Health Innovation LLC Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million.	Finance
Sprout Bioventures Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions.	Finance
Dogma Therapeutics, Inc. Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease	Health Technology